GENB
Generate Biomedicines, Inc.
NASDAQ · Financial Services · Asset Management · US
$14.46
−8.33%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 32.5M | 31.9M | 20.5M |
| Cost of Revenue | 3.3M | — | — |
| Gross Profit | 29.2M | 31.9M | 20.5M |
| Operating Expenses | |||
| R&D Expense | 225.5M | 224.7M | 175.3M |
| SG&A Expense | 47.8M | 42.3M | 42.1M |
| General & Admin Expense | 34.3M | 42.3M | 42.1M |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | — | — | — |
| Total Operating Expenses | 273.2M | 267.0M | 217.4M |
| Cost and Expenses | 276.5M | 267.0M | 217.4M |
| Operating Income (EBIT) | (244.0M) | (235.1M) | (196.9M) |
| Non-Operating | |||
| Interest Income | 15.6M | 13.7M | 18.1M |
| Interest Expense | 1.0M | 1.1M | 2.1M |
| Net Interest Income | 14.6M | 12.5M | 16.0M |
| Other Non-Op Income/Expense | 14.2M | 12.3M | 15.8M |
| Non-Operating Income (excl Interest) | (12.6M) | (13.4M) | (17.9M) |
| EBT (Pre-Tax Income) | (229.8M) | (222.8M) | (181.2M) |
| Income Tax Expense | 181.0K | 163.0K | 212.0K |
| Bottom Line | |||
| Net Income | (222.8M) | (203.2M) | (173.8M) |
| Earnings from Cont. Ops | (230.0M) | (223.0M) | (181.4M) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (253.7M) | (249.5M) | (213.8M) |
| Per Share | |||
| Basic EPS | ($2.21) | ($4.98) | ($1.68) |
| Diluted EPS | ($2.21) | ($4.98) | ($1.68) |
| Revenue Per Share | $0.25 | $0.64 | $0.16 |
| Shares | |||
| Basic Shares Outstanding | 128.2M | 50.1M | 127.5M |
| Diluted Shares Outstanding | 128.2M | 50.1M | 127.5M |
| Profitability Metrics | |||
| EBITDA | (218.2M) | (208.5M) | (163.7M) |
| D&A | 13.2M | 13.2M | 15.3M |
| EBIT | (231.4M) | (221.7M) | (179.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026